2021
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis.
Feher A, Boutagy NE, Oikonomou EK, Thorn S, Liu YH, Miller EJ, Sinusas AJ, Hinchcliff M. Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis. The Journal Of Rheumatology 2021, 48: 1574-1582. PMID: 34266986, PMCID: PMC10275580, DOI: 10.3899/jrheum.210040.Peer-Reviewed Original ResearchConceptsReduced Myocardial Flow ReserveMyocardial flow reserveRaynaud's phenomenonPrimary Raynaud's phenomenonSecondary Raynaud's phenomenonPatient controlsHealthy participantsFlow reservePositron Emission Tomography/Computed TomographyEmission Tomography/Computed TomographyTomography/Computed TomographyPositron emission tomography/Impaired Myocardial Flow ReserveCoronary microvascular dysfunctionLarge prospective studiesMultivariable logistic regressionEmission tomography/PET/CTSSc-RPMicrovascular dysfunctionClinical predictorsIndependent predictorsSystemic sclerosisPrognostic valueProspective study
2005
Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders.
Yoshinaga K, Chow BJ, dekemp RA, Thorn S, Ruddy TD, Davies RA, DaSilva JN, Beanlands R. Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders. Current Pharmaceutical Design 2005, 11: 903-32. PMID: 15777243, DOI: 10.2174/1381612053381800.Peer-Reviewed Original ResearchConceptsVivo pharmacokinetic studyDrug deliveryMolecular probesCardiovascular diseaseEffect of therapyAccuracy of PETPET/CTNon-invasive imaging modalityEvaluation of drugsMolecular imagingPositron emission tomography (PET) imagingEmission Tomography ImagingPositron emission tomographyPotential of PETNon-invasive modalityMechanism of actionPharmacokinetic studyCardiac molecular imagingEarly drug developmentAdvantages of PETDrug therapyDisease progressionSerial evaluationDrug treatmentReceptor levels